Showing results (1461-1470 of 1,490) with videos related to

Sort By:
Pageof 149
Journal of Cellular Physiology|December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experienceLaura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
Nature Metabolism|June 12, 2024
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, et al.
Breast (Edinburgh, Scotland)|May 27, 2025
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitorsRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
The Oncologist|October 19, 2024
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide populationFederica Lo Prinzi, Francesca Salani, Margherita Rimini, et al.
Oncology|August 15, 2025
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapyFrancesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, et al.
The Oncologist|April 17, 2026
Comparative real-world Progression Free Survival of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer Patients with Bone MetastasesRoberta Scafetta, Marco Donato, Carla Gullotta, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 17, 2025
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D IndexMara Persano, Margherita Rimini, Francesca Salani, et al.
European Journal of Cancer (Oxford, England : 1990)|October 12, 2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumabChiara Pirrone, Umberto Malapelle, Francesco Pepe, et al.
Journal of the National Cancer Institute|July 3, 2025
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide populationMargherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, et al.
Pageof 149